Aldevron and Minaris Renew Strategic Partnership to Accelerate Gene-Modified Cell Therapy Development
Key Insights
Aldevron (search) and Minaris (search) have renewed their licensing agreement to expand access to proprietary lentiviral plasmid systems for gene-modified cell therapy applications.
The partnership provides developers with off-the-shelf access to Aldevron (search)'s pALD-Lenti plasmid system, supporting CAR-T (search), TCR-T (search), and other gene-modified cell therapies across research and cGMP quality grades.
The collaboration combines Minaris (search)' Oxgene (search) plasmid design expertise with Aldevron (search)'s manufacturing capabilities to reduce development timelines and supply chain complexity.
Aldevron (search), a Danaher (search) company and global leader in DNA, RNA and protein production for genomic medicine, and Minaris (search), a global cell and gene therapy contract development and manufacturing organization (CDMO), have announced a renewed licensing agreement that expands access to a proprietary lentiviral plasmid system for gene-modified cell therapy applications. The updated agreement is designed to help developers simplify supply chains, reduce risk, and accelerate programs from discovery to clinical trials.
Strategic Partnership Expansion
The renewed agreement builds on Aldevron (search)'s established partnership with Oxgene (search), a Minaris (search) brand whose lentiviral plasmid designs have been widely adopted across the cell and gene therapy ecosystem. Under the expanded partnership, Aldevron will continue to manufacture and offer these plasmids across research, GMP Source™ quality grade, and full cGMP standards, providing clients with immediate access to regulatory-ready starting materials.
The collaboration also provides access to the Oxgene (search) Development Centre in London, where experts can optimize plasmids and genes of interest to enhance viral vector productivity and overall process performance.
Complete Plasmid Platform for Cell Therapy Applications
Aldevron (search)'s pALD-Lenti plasmid system represents a complete, four-plasmid platform optimized for lentiviral vector production. The system supports multiple gene-modified cell therapy applications, including CAR-T (search), TCR-T (search), and other advanced therapeutic modalities. By offering off-the-shelf availability at multiple quality grades, the platform helps developers reduce lead times, simplify supply chains, and accelerate development timelines.
"Our collaboration with Minaris (search) brings together complementary strengths—world-class plasmid design and cGMP manufacturing innovation—in a way that reduces risk and complexity for developers at every stage of the pipeline," said Venkata Indurthi, Chief Science Officer for Aldevron (search). "By delivering phase appropriate starting materials backed by deep manufacturing and quality expertise, Aldevron is helping compress development timelines and move innovative therapies from discovery to the clinic with greater speed, confidence, and scalability."
Oxgene's Role in Advanced Vector Technologies
Oxgene (search) serves as Minaris (search)' innovation engine and center of excellence for advanced technologies, including viral vectors through TESSA® (AAV) and XOFLX™ (LVV) platforms. The division provides expertise in vector design, plasmids, and cell line development, functioning as an integrated component of Minaris' global CDMO capabilities to deliver end-to-end solutions for advanced therapy development.
"Through our Oxgene (search) Center of Excellence in London, we bring deep expertise in plasmid design and engineering that is grounded in real-world vector development and manufacturing experience," said Eytan Abraham, PhD, Chief Technology and Commercial Officer at Minaris (search). "Our focus has always been on designing robust, high-performing plasmid systems that translate seamlessly into scalable vector production. By combining that design expertise with Aldevron (search)'s manufacturing strength, we help ensure developers have reliable, high-quality starting materials that reduce risk, streamline development, and support a clear path toward clinical and commercial success."
Industry Impact and Manufacturing Capabilities
The agreement reflects the growing demand for consistent, scalable, and high-quality plasmid DNA solutions that support progress across gene-modified cell therapy programs. Aldevron (search), founded in 1998 and now part of Danaher (search) Corporation, has supported landmark achievements in the field, including playing a key role in manufacturing the world's first mRNA-based personalized CRISPR therapy.
Minaris (search) brings more than 25 years of cell and gene therapy development and manufacturing expertise, combined with over 40 years in biosafety testing. The company operates as a fully U.S.-owned organization with state-of-the-art GMP facilities across five global sites on three continents. Through its divisions, Minaris Advanced Therapies and Minaris Advanced Testing, the company supports innovators from IND applications through commercial supply, delivering GMP analytics, biosafety, viral clearance, and product characterization services across cell and gene therapies and biologics.